Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Celgene announces takeover of Juno Therapeutics

Celgene announces takeover of Juno Therapeutics

23rd January 2018

Celgene has announced the acquisition of Juno Therapeutics in a deal worth $9 billion (GBP 6.45 billion).

Juno is a recognised pioneer in the development of CAR-T and TCR therapeutics, with a broad portfolio spanning multiple targets and cancer indications. This includes JCAR017, a potentially best-in-class CD19-directed CAR-T currently being assessed as a treatment for large B-cell lymphoma.

Regulatory approval for JCAR017 in the US is expected in 2019, with potential global peak sales of the product estimated at approximately $3 billion. As such, the acquisition of Juno is expected to significantly bolster Celgene's position in the field of cellular immunotherapy.

In collaboration with Juno's team in Seattle, Celgene plans to expand its existing centre of excellence for immuno-oncology translational medicine, by leveraging Juno's research and manufacturing facilities in Seattle and Bothell.

Mark Alles, Celgene's chief executive officer, said: "Juno's advanced cellular immunotherapy portfolio and research capabilities strengthen Celgene's global leadership in haematology and adds new drivers for growth beyond 2020."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

We currently have 10 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.